{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:03:23Z","timestamp":1786982603244,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s13300-021-01047-5","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T15:12:30Z","timestamp":1616080350000},"page":"1415-1427","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Effects of Sodium Glucose Co-Transporter\u00a02 Inhibitors in Type\u00a01 Diabetes Mellitus on Body Composition and Glucose Variabilities: Single-Arm, Exploratory Trial"],"prefix":"10.1007","volume":"12","author":[{"given":"Yusuke","family":"Baba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2535-5396","authenticated-orcid":false,"given":"Ryoichi","family":"Ishibashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Takasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiho","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuko","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Tokita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miwako","family":"Meguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Harama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiichi","family":"Hirayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Koshizaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiro","family":"Maezawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daigaku","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitaka","family":"Okajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,18]]},"reference":[{"key":"1047_CR1","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.2337\/dc18-1446","volume":"42","author":"J Edqvist","year":"2019","unstructured":"Edqvist J, Rawshani A, Adiels M, et al. BMI, mortality, and cardiovascular outcomes in type\u00a01 diabetes: findings against an obesity paradox. Diabetes Care. 2019;42:1297\u2013304.","journal-title":"Diabetes Care"},{"key":"1047_CR2","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type\u00a02 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"1047_CR3","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type\u00a02 diabetes. N Engl J Med. 2019;380:347\u201357.","journal-title":"N Engl J Med"},{"key":"1047_CR4","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type\u00a02 diabetes. N Engl J Med. 2017;377:644\u201357.","journal-title":"N Engl J Med"},{"key":"1047_CR5","doi-asserted-by":"publisher","first-page":"44128","DOI":"10.1038\/srep44128","volume":"7","author":"J Chen","year":"2017","unstructured":"Chen J, Fan F, Wang JY, et al. The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type\u00a01 diabetes: a systematic review and meta-analysis. Sci Rep. 2017;7:44128.","journal-title":"Sci Rep"},{"key":"1047_CR6","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1507\/endocrj.EJ15-0749","volume":"63","author":"C Yamamoto","year":"2016","unstructured":"Yamamoto C, Miyoshi H, Ono K, et al. Ipragliflozin effectively reduced visceral fat in Japanese patients with type\u00a02 diabetes under adequate diet therapy. Endocr J. 2016;63:589\u201396.","journal-title":"Endocr J"},{"key":"1047_CR7","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1111\/dom.13421","volume":"20","author":"Y Tsurutani","year":"2018","unstructured":"Tsurutani Y, Nakai K, Inoue K, et al. Comparative study of the effects of ipragliflozin and sitagliptin on multiple metabolic variables in Japanese patients with type\u00a02 diabetes: a multicentre, randomized, prospective, open-label, active-controlled study. Diabetes Obes Metab. 2018;20:2675\u20139.","journal-title":"Diabetes Obes Metab"},{"key":"1047_CR8","doi-asserted-by":"publisher","first-page":"467","DOI":"10.5551\/jat.40873","volume":"25","author":"S Sugiyama","year":"2018","unstructured":"Sugiyama S, Jinnouchi H, Kurinami N, et al. Dapagliflozin reduces fat mass without affecting muscle mass in type\u00a02 diabetes. J Atheroscler Thromb. 2018;25:467\u201376.","journal-title":"J Atheroscler Thromb"},{"key":"1047_CR9","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1111\/dom.13750","volume":"21","author":"M Koshizaka","year":"2019","unstructured":"Koshizaka M, Ishikawa K, Ishibashi R, et al. Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type\u00a02 diabetes treated with sitagliptin: a prospective, multicentre, open-label, blinded-endpoint, randomized controlled study (PRIME-V study). Diabetes Obes Metab. 2019;21:1990\u20135.","journal-title":"Diabetes Obes Metab"},{"key":"1047_CR10","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type\u00a02 diabetes and nephropathy. N Engl J Med. 2019;380:2295\u2013306.","journal-title":"N Engl J Med"},{"key":"1047_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-020-00971-2","author":"R Ishibashi","year":"2020","unstructured":"Ishibashi R, Baba Y, Kakinuma K, et al. Assessing patient satisfaction following sodium glucose co-transporter\u00a02 inhibitor treatment for type\u00a01 diabetes mellitus: a prospective study in Japan. Diabetes Ther. 2020. https:\/\/doi.org\/10.1007\/s13300-020-00971-2.","journal-title":"Diabetes Ther"},{"key":"1047_CR12","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1089\/dia.2018.0246","volume":"20","author":"SK Garg","year":"2018","unstructured":"Garg SK, Peters AL, Buse JB, Danne T. Strategy for mitigating DKA risk in patients with type\u00a01 diabetes on adjunctive treatment with SGLT inhibitors: a STICH protocol. Diabetes Technol Ther. 2018;20:571\u20135.","journal-title":"Diabetes Technol Ther"},{"key":"1047_CR13","doi-asserted-by":"publisher","first-page":"F942","DOI":"10.1152\/ajprenal.00129.2018","volume":"315","author":"A Edwards","year":"2018","unstructured":"Edwards A, Bonny O. A model of calcium transport and regulation in the proximal tubule. Am J Physiol Renal Physiol. 2018;315:F942\u201353.","journal-title":"Am J Physiol Renal Physiol"},{"key":"1047_CR14","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/jdi.12851","volume":"10","author":"T Sasaki","year":"2019","unstructured":"Sasaki T, Sugawara M, Fukuda M. Sodium-glucose cotransporter\u00a02 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: the components of weight loss in Japanese patients with type\u00a02 diabetes mellitus) study. J Diabetes Investig. 2019;10:108\u201317.","journal-title":"J Diabetes Investig"},{"key":"1047_CR15","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1517\/14740338.2015.1034105","volume":"14","author":"D Yabe","year":"2015","unstructured":"Yabe D, Nishikino R, Kaneko M, Iwasaki M, Seino Y. Short-term impacts of sodium\/glucose co-transporter\u00a02 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse events. Expert Opin Drug Saf. 2015;14:795\u2013800.","journal-title":"Expert Opin Drug Saf"},{"key":"1047_CR16","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s10522-018-9775-3","volume":"19","author":"R McCormick","year":"2018","unstructured":"McCormick R, Vasilaki A. Age-related changes in skeletal muscle: changes to life-style as a therapy. Biogerontology. 2018;19:519\u201336.","journal-title":"Biogerontology"},{"key":"1047_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13340","author":"M Koshizaka","year":"2020","unstructured":"Koshizaka M, Ishikawa K, Ishibashi R, et al. Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type\u00a02 diabetes mellitus: subanalysis of a prospective, randomized, controlled study (PRIME-V study). J Diabetes Investig. 2020. https:\/\/doi.org\/10.1111\/jdi.13340.","journal-title":"J Diabetes Investig"},{"key":"1047_CR18","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1111\/dom.13260","volume":"20","author":"T Yamada","year":"2018","unstructured":"Yamada T, Shojima N, Noma H, Yamauchi T, Kadowaki T. Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type\u00a01 diabetes mellitus: systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2018;20:1755\u201361.","journal-title":"Diabetes Obes Metab"},{"key":"1047_CR19","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.2337\/dc15-1730","volume":"38","author":"RR Henry","year":"2015","unstructured":"Henry RR, Thakkar P, Tong C, Polidori D, Alba M. Efficacy and safety of canagliflozin, a sodium-glucose cotransporter\u00a02 inhibitor, as add-on to insulin in patients with type\u00a01 diabetes. Diabetes Care. 2015;38:2258\u201365.","journal-title":"Diabetes Care"},{"key":"1047_CR20","doi-asserted-by":"publisher","first-page":"400","DOI":"10.2337\/dc18-1444","volume":"42","author":"RW Beck","year":"2019","unstructured":"Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care. 2019;42:400\u20135.","journal-title":"Diabetes Care"},{"key":"1047_CR21","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1172\/JCI72227","volume":"124","author":"E Ferrannini","year":"2014","unstructured":"Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter\u00a02 inhibition in type\u00a02 diabetic patients. J Clin Invest. 2014;124:499\u2013508.","journal-title":"J Clin Invest"},{"issue":"72","key":"1047_CR22","first-page":"366","volume":"1992","author":"LB Houtkooper","year":"1985","unstructured":"Houtkooper LB, Going SB, Lohman TG, Roche AF, Van Loan M. Bioelectrical impedance estimation of fat-free body mass in children and youth: a cross-validation study. J Appl Physiol. 1985;1992(72):366\u201373.","journal-title":"J Appl Physiol"},{"key":"1047_CR23","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3390\/nu10060738","volume":"10","author":"SY Lee","year":"2018","unstructured":"Lee SY, Ahn S, Kim YJ, et al. Comparison between dual-energy X-ray absorptiometry and bioelectrical impedance analyses for accuracy in measuring whole body muscle mass and appendicular skeletal muscle mass. Nutrients. 2018;10:738.","journal-title":"Nutrients"},{"key":"1047_CR24","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jocd.2018.02.003","volume":"21","author":"BS Nickerson","year":"2018","unstructured":"Nickerson BS, Tinsley GM. Utilization of BIA-derived bone mineral estimates exerts minimal impact on body fat estimates via multicompartment models in physically active adults. J Clin Densitom. 2018;21:541\u20139.","journal-title":"J Clin Densitom"},{"key":"1047_CR25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s13300-016-0223-6","volume":"8","author":"T Haak","year":"2017","unstructured":"Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type\u00a02 diabetes: a multicentre, open-label randomized controlled trial. Diabetes Ther. 2017;8:55\u201373.","journal-title":"Diabetes Ther"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-021-01047-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-021-01047-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-021-01047-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T03:18:33Z","timestamp":1620184713000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-021-01047-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,18]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["1047"],"URL":"https:\/\/doi.org\/10.1007\/s13300-021-01047-5","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,18]]},"assertion":[{"value":"25 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}